TransMedics, Inc., an Andover, MA-based medical technology company dedicated to improving organ tranplant procedures, closed a $51.2m growth equity financing.
The round was co-led by global life science investors Fayerweather Fund, Pharmstandard International S.A. represented by InBio Ventures, Ervington Investments, and BioStar Ventures, with participation from existing investors Abrams Capital, Lung Biotechnology PBC, Flagship Ventures and Kleiner Perkins Caufield Byers.
Led by Dr. Waleed Hassanein, President and CEO, TransMedics has developed the Organ Care System (OCS™), a technology and multi-organ platform to improve outcomes for transplant patients and to increase the number of transplantable organs worldwide. The OCS™ portable technology maintains donor organs in a near-physiologic state outside of the human body and addresses the current limitations of cold storage.
The OCS™ Heart and OCS™ Lung systems are CE Marked and used by transplant centers in Europe, Australia and Canada. These two and the OCS™ Liver systems are in clinical trials in the United States.